Agios Pharmaceuticals Inc. (AGIO), a commercial stage biopharmaceutical company, on Friday announced discontinuation of development on the Phase 2b trial for Tebapivat in treating lower-risk myelodysplastic syndrome (LR-MDS).
Tebapivat is a next-generation oral pyruvate kinase activator, developed for the treatment of hematological diseases.
The open-label, multicenter, dose-finding Phase 2b trial evaluated a once-daily dose of tebapivat in 65 patients of LR-MDS and anemia. The primary endpoint was defined as a state of transfusion-independence in patients at 24 weeks, indicating successful repair of red blood cells.
The company stated that the trial did not meet the pre-established threshold of results to justify continuation. However, the drug was tolerated in patients across all doses.
The drug is also being advanced in a Phase 2 trial for the treatment of sickle cell disease, with topline data expected in the second half of 2026.
AGIO is currently trading at $29.39, down 3.39%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.